The Company announced it submitted a supplemental New Animal Drug Application (NADA) for NOCITA® (bupivacaine liposome injectable suspension) with the U.S. Food and Drug Administration’s Center for Veterinary Medicine (CVM).
The Company plans on presenting at Jefferies 2018 Global Healthcare Conference on Tuesday, June 5, 2018 at 4:30 p.m. ET in New York City.
Aratana Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results
Attend our Emerging Therapeutic Technologies CE sessions on Tuesday, March 8 and Wednesday, March 9 to discover novel therapeutics in development for osteoarthritis, post-operative pain, inappetence, lymphoma and osteosarcoma.
The Aratana CE dinner program was an informative evening for VOS attendees. On the evening of February 29 in Big Sky, Montana, conference attendees learned about new therapeutics in development for their patients from Aratana.
The Company plans to present at the Barclays Capital Global Healthcare Conference on Wednesday, March 16 at 3:50 p.m. ET in Miami at the Loews Miami Beach Hotel.
VOS meeting attendees are invited to the Aratana CE dinner program to learn about new therapeutic solutions in development for their patients.
The Company received a technical section complete letter for effectiveness from the U.S. Food and Drug Administration’s Center for Veterinary Medicine (CVM) for a therapeutic for appetite stimulation in dogs.
The Company will host a live conference call on Tuesday, March 15, 2016 at 8:30 a.m. ET to discuss financial results for the fourth quarter ending December 31, 2015 and the full year.
The Company received a technical section complete letter for effectiveness from the U.S. Food and Drug Administration’s Center for Veterinary Medicine (CVM) for a therapeutic to provide local post-operative analgesia for cranial cruciate ligament surgery in dogs.
The Company has filed a Marketing Authorization Application with the European Medicines Agency (EMA) for a therapeutic intended to treat pain and inflammation in dogs with osteoarthritis.
Discover how we’re working to raise the standard of care with novel therapeutics in development for osteoarthritis, post-operative pain, inappetence, lymphoma and osteosarcoma.
Aratana made a strong connection with nearly 1,000 veterinary professionals at their sponsored, main event. Dr. Steven St. Peter opened the event with an introduction to Aratana and introduced the authors of the New York Times best selling book, Zoobiquity: The Astonishing Connection Between Human and Animal Health.
The Company filed an administrative New Animal Drug Application (NADA) with the Food and Drug Administration’s Center for Veterinary Medicine (CVM) for a therapeutic designed to control pain and inflammation in dogs with osteoarthritis.
Dr. Steven St. Peter, CEO and President of Aratana Therapeutics, was named Visionary CEO by Animal Pharm.
The human and animal connection is deeper than just the bond we have with our pets and that our pets have with us – the similarities are in our DNA and how our biological systems function.
The Company will present at the Bank of America Merrill Lynch 2015 Animal Health Summit in Boston at 8 a.m. ET.
On December 11, Julia Stephanus was featured in an article highlighting the importance of inspiring girls to explore careers in STEM, specifically in the animal health industry.